Welcome to our dedicated page for Zimmer Biomet Holdings news (Ticker: ZBH), a resource for investors and traders seeking the latest updates and insights on Zimmer Biomet Holdings stock.
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) is a preeminent global leader in musculoskeletal healthcare. Headquartered in Warsaw, Indiana, Zimmer Biomet has been at the forefront of advancing bone and joint health for nearly 90 years. The company designs, manufactures, and markets a comprehensive range of orthopedic implants and surgical equipment, addressing joint reconstruction, bone repair, sports medicine, spine, and dental reconstruction. Its innovative product portfolio includes the ROSA® Robotics systems for knee, hip, and shoulder replacements, and the TMINI Miniature Robotic System for total knee arthroplasty.
Zimmer Biomet's latest endeavors include the establishment of a dedicated Health Equity division in 2023, which aims to integrate health equity into the company's core strategies and operations. This division has already made significant strides by assembling a strategic advisory board and developing the Community Centered Care (C3) framework to increase patient access to quality care in underserved communities.
In addition, Zimmer Biomet has recently partnered with top pickleball organizations in the U.S., underscoring its commitment to joint health and well-being for the growing community of pickleball players. The company also announced a strategic alliance with CBRE Group, Inc. to expand orthopedic ambulatory surgery centers across the country, and a collaboration with RevelAi Health to commercialize AI-powered engagement solutions aimed at advancing value-based orthopedic care and health equity.
Financially, Zimmer Biomet has demonstrated robust performance, with first-quarter 2024 net sales amounting to $1.889 billion, a 3.2% year-over-year increase. The company continues to focus on innovation, operational excellence, and strategic partnerships to drive growth and enhance shareholder value. For more information, visit www.zimmerbiomet.com or follow them on LinkedIn and Twitter.
Zimmer Biomet, a global leader in medical technology, announced plans to present at two key healthcare conferences. The management team will participate in the Bank of America Securities 2023 Healthcare Conference on May 10, 2023, at 1:40 p.m. ET. They will also present at the Jefferies Healthcare Conference on June 7, 2023. Investors can access a live webcast of both presentations on the ZBH Investor Relations website, with archived replays available after the events. With over 90 years of experience, Zimmer Biomet focuses on advancing patient mobility through innovative products and integrated technologies.
Zimmer Biomet Holdings (NYSE: ZBH), a leader in medical technology, will present at the Needham Virtual Healthcare Conference on April 18, 2023, at 10:15 a.m. ET. The presentation will be made by members of Zimmer Biomet's management team and will be accessible via their Investor Relations website. The conference aims to showcase innovative healthcare solutions that enhance patient mobility and health. Zimmer Biomet has a legacy of over 90 years in providing quality medical solutions and operates in 25+ countries worldwide, demonstrating their commitment to innovation.
Zimmer Biomet Holdings has announced that its first-quarter earnings conference call will be webcast on May 2, 2023, at 8:30 a.m. ET. A news release featuring the quarterly results will be available on the same day at 6:30 a.m. ET. The event will be accessible on Zimmer Biomet's Investor Relations website. Interested U.S. and Canadian participants can join by calling (888) 204-4368, while international callers should dial +1 (323) 994-2093, both using conference ID 5103691. Zimmer Biomet continues to lead in medical technology, aiming to enhance patient mobility and health through innovative products and technologies.
Zimmer Biomet Holdings, a global leader in medical technology, has approved a cash dividend of $0.24 per share for Q1 2023. This dividend will be payable on April 28, 2023, to stockholders of record by the close of business on March 29, 2023. The company's commitment to returning value to shareholders demonstrates its financial health and confidence in future growth. With over 90 years in the industry, Zimmer Biomet continues to enhance patient experiences through innovative products and advanced technologies.
Zimmer Biomet (NYSE: ZBH) announced the unveiling of enhancements to its ZBEdge™ Dynamic Intelligence™ at the AAOS 2023 Annual Meeting in Las Vegas. Key updates include the mymobility® Digital Care Management Platform, which supports patient recovery through continuous data collection, and the Persona IQ®, a smart knee implant for gathering kinematic data. The ROSA® Knee system received improvements for better surgical outcomes. COO Ivan Tornos highlighted the potential of these innovations to enhance decision-making and patient care.
Zimmer Biomet reported Q4 2022 net sales of $1.825 billion, up 2.7% year-over-year, with an 8.3% increase on a constant currency basis. The Q4 diluted loss per share was $0.62, whereas adjusted diluted EPS was $1.88. For the full year, net sales reached $6.940 billion, a 1.6% increase, and an adjusted EPS of $6.89. The company anticipates a 2023 revenue growth of 1.5% - 3.5% and adjusted EPS between $6.95 - $7.15. Recent highlights include FDA clearance for the Persona OsseoTi Keel Tibia and the acquisition of Embody, Inc.
Zimmer Biomet Holdings, Inc. (ZBH) announced its fourth quarter earnings conference call scheduled for February 3, 2023, at 8:30 a.m. ET. A news release detailing quarterly results will be available at 6:30 a.m. ET that day. Participants can access the live audio webcast via Zimmer Biomet's Investor Relations website. Those in the U.S. and Canada can join by dialing (888) 204-4368, while international callers should dial +1 (323) 994-2093 with conference ID 5103691.
Zimmer Biomet (ZBH) announced a definitive agreement to acquire Embody, Inc. for $155 million at closing and up to an additional $120 million based on future milestones. This acquisition aims to enhance Zimmer Biomet's sports medicine portfolio, notably through Embody's collagen-based solutions for orthopedic injuries, including the TAPESTRY® implants. The deal is expected to drive revenue growth while being slightly dilutive to adjusted earnings per share in 2023. Completion is anticipated in February 2023.
Zimmer Biomet Holdings (ZBH) has declared a quarterly cash dividend of $0.24 per share for Q4 2022, payable on January 31, 2023, to stockholders on record as of December 27, 2022. This decision reflects the company's commitment to returning value to its investors and underscores its financial stability. With a rich history of over 90 years in the medical technology sector, Zimmer Biomet continues to innovate and expand its product offerings globally.
Zimmer Biomet Holdings (NYSE: ZBH) announces its participation in two significant conferences. Members of the Executive Management Team will present at the Goldman Sachs CEOs Unscripted Conference on January 5, 2023, at 11:25 a.m. ET, and at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 3:45 p.m. PT / 6:45 p.m. ET. A live webcast will be available on the company's Investor Relations website and archived for later access.
FAQ
What is the current stock price of Zimmer Biomet Holdings (ZBH)?
What is the market cap of Zimmer Biomet Holdings (ZBH)?
What does Zimmer Biomet do?
Where is Zimmer Biomet headquartered?
What are Zimmer Biomet's latest innovations?
What is Zimmer Biomet's focus on health equity?
How did Zimmer Biomet perform financially in the first quarter of 2024?
What are Zimmer Biomet's partnerships?
What is the ROSA® Robotics system?
What is the Community Centered Care (C3) framework?
What is Zimmer Biomet's role in pickleball?
How does Zimmer Biomet contribute to innovation in healthcare?
